Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, M.D. [interview by John S. James] Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, M.D. [interview by John S. James] Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.

AIDS Treat News. 1996 Aug 23;(No 253):1-2. Unique Identifier : AIDSLINE AIDS/96701859
Scheibel S


Abstract: In an interview with AIDS Treatment News, Steven F. Scheibel, M.D. discusses the results of two small studies in San Francisco that reported good HIV suppression with regimens of five-drug and six-drug antiretroviral therapy. The studies included a clinical trial of 6 patients infected with HIV-1 within the past 6 months and an observational study of 15 patients with prolonged HIV infection. In both studies, patients were treated with a low-dose combination of AZT, ddI, ddC, and interferon-alpha, with most also taking a protease inhibitor. All of the recent seroconverters and many of the longer term patients achieved undetectable HIV RNA as measured by the Roche Ultradirect Monitor assay. Future research plans for Dr. Scheibel include the study of the HIV proviral DNA load and changes that occur with combination antiretroviral therapies.
Keywords: Antiviral Agents/*ADMINISTRATION & DOSAGE Drug Therapy, Combination HIV Infections/*DRUG THERAPY/VIROLOGY *HIV-1/ISOLATION & PURIF Human NEWSLETTER ARTICLE INTERVIEWKWDantiviralagents/KWDadministration&dosagedrugtherapy,combinationhivinfections/KWDdrugtherapy/virologyKWDhiv-1/isolation&purifhumannewsletterarticleinterview
961230
M96C1439

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .